<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983823</url>
  </required_header>
  <id_info>
    <org_study_id>28/21</org_study_id>
    <nct_id>NCT04983823</nct_id>
  </id_info>
  <brief_title>Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)</brief_title>
  <official_title>Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE): A Randomised Controlled Trial of the Role of Optimal Cardioprotection Strategies to Prevent Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baker Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baker Heart and Diabetes Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study in which a process of identifying and reducing heart failure (HF)&#xD;
      risk will be applied to COVID-19 survivors &gt;50 years old.&#xD;
&#xD;
      The overall goal of this study to identify the feasibility and value of risk-guided medical&#xD;
      therapy and exercise intervention in COVID-19 survivors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants enrolled in this study will be randomized to a cardio-COVID disease management&#xD;
      plan (CC-DMP) that involves the use of surveillance imaging to detect subclinical left&#xD;
      ventricular dysfunction (LVD), clinical review to ensure optimal risk factor control and&#xD;
      cardio-protection and exercise intervention. The program will be delivered over a period of&#xD;
      24 months.&#xD;
&#xD;
      The outcome from this study will show that subclinical LVD is common among COVID-19&#xD;
      survivors, and a CC-DMP is feasible in reducing HF risk factors in this sub group of&#xD;
      survivors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization to CC-DMP or usual care</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcomes assessor will receive study data based on pooled de identified dataset.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>New onset heart failure</measure>
    <time_frame>Over a period of 24 months</time_frame>
    <description>Symptoms and signs of heart failure (Framingham criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in exercise capacity</measure>
    <time_frame>Over a period of 24 months</time_frame>
    <description>Cardio pulmonary fitness (peak oxygen uptake (VO2 peak)) from baseline to follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximal isometric grip strength</measure>
    <time_frame>Over a period of 24 months</time_frame>
    <description>Strength (kg) measured by electronic dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on quality of life</measure>
    <time_frame>Over a period of 24 months</time_frame>
    <description>Change in score on Health related quality of life: Assessment of quality of life 8 Dimension.&#xD;
Minimum value 1, Maximum value 4. Higher values indicate worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">820</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Heart failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimization of pharmacotherapy:&#xD;
This will be performed by a supervising clinician and will comprise treatment with angiotensin-converting enzyme inhibitor (ACEi, Ramipril) and beta blocker (Metoprolol) for cardioprotection.&#xD;
Exercise intervention: Individualized training program will be provided by an exercise physiologist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All medical management for participants allocated to this group will be at the discretion of their usual care healthcare professional(s).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)</intervention_name>
    <description>A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.</description>
    <arm_group_label>Heart failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>This will be provided by participants' usual healthcare professional(s).</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. History of COVID-19 infection&#xD;
&#xD;
          2. Live within a geographically accessible area for follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Valvular stenosis or regurgitation of &gt;moderate severity&#xD;
&#xD;
          2. History of previous heart failure (baseline New York Heart Association (NYHA)&#xD;
             classification &gt;2)&#xD;
&#xD;
          3. Inability to acquire interpretable images (identified from baseline echo)&#xD;
&#xD;
          4. Contraindications to beta blockers or angiotensin-converting enzyme inhibitors&#xD;
&#xD;
          5. Oncologic (or other) life expectancy &lt;12 months or any other medical condition&#xD;
             (including pregnancy) that results in the belief (deemed by the Chief Investigators)&#xD;
             that it is not appropriate for the patient to participate in this trial&#xD;
&#xD;
          6. Already taking both angiotensin converting enzyme inhibitors/ angiotensin receptor&#xD;
             blockers and beta blockers, or intolerance (or allergy) to both.&#xD;
&#xD;
          7. Mobility impairment that would impact participants' ability to perform exercise&#xD;
&#xD;
          8. Unable to provide written informed consent to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas H Marwick, MD,PhD,MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baker Heart and Diabetes Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anjali Haikerwal, MBBS,MPH,PhD</last_name>
    <phone>+61385321964</phone>
    <email>anjali.haikerwal@baker.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas H Marwick, MD,PhD,MPH</last_name>
    <phone>+61385321550</phone>
    <email>tom.marwick@baker.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baker Heart and Diabetes Institute</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>COVID</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data sharing based available on application to the study PI</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

